--- title: "Dr. Reddy's Laboratories (DRREDDY) stock and investor profile" url: "https://aibio.space/companies/dr-reddy-s-laboratories/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "Dr. Reddy's Laboratories Ltd. (NSE: DRREDDY), India. The directory classifies it as Biopharma / pharmaceutical profile checked." --- DRREDDY Dr. Reddy's Laboratories Ltd. NSE · India # Dr. Reddy's Laboratories (DRREDDY) news Dr. Reddy's Laboratories Ltd. is a public biotech or pharmaceutical company listed on NSE under the ticker DRREDDY, recorded under India. The directory classifies it as Biopharma / pharmaceutical profile checked. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. ## Latest Dr. Reddy's Laboratories news We have not published a story on Dr. Reddy's Laboratories yet. When there is news, it will appear here. ## Dr. Reddy's Laboratories at a glance - **Ticker**: DRREDDY - **Listing**: NSE - **Country**: India - **Cash, Mar 31, 2025**: $678.0 million ### Related companies - [Zim Laboratories](https://aibio.space/companies/zim-laboratories/) NSE: ZIMLAB - [Sun Pharma Advanced Research Co.](https://aibio.space/companies/sun-pharma-advanced-research/) NSE: SPARC - [Zenith Healthcare](https://aibio.space/companies/zenith-healthcare/) BSE: ZENITHHE - [Zenotech Laboratories](https://aibio.space/companies/zenotech-laboratories/) BSE: ZENOTECH - [Bio Medica Laboratories](https://aibio.space/companies/bio-medica-laboratories/) NSE: BMLL - [Ishita Drugs & Industries](https://aibio.space/companies/ishita-drugs-industries/) BSE: ISHITADR - [Gujarat Terce Laboratories](https://aibio.space/companies/gujarat-terce-laboratories/) BSE: GUJTERC - [Divi's Laboratories](https://aibio.space/companies/divi-s-laboratories/) NSE: DIVISLAB ### Also on NSE - [Accent Microcell](https://aibio.space/companies/accent-microcell/) ACCENTMIC - [Biocon](https://aibio.space/companies/biocon/) BIOCON - [TTK Healthcare](https://aibio.space/companies/ttk-healthcare/) TTKHLTCARE - [Panacea Biotec](https://aibio.space/companies/panacea-biotec/) PANACEABIO - [NATCO Pharma](https://aibio.space/companies/natco-pharma/) NATCOPHARM - [Windlas Biotech](https://aibio.space/companies/windlas-biotech/) WINDLAS ## What Dr. Reddy's Laboratories does Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company, established in 1984, that aims to accelerate access to affordable and innovative medicines. Its reportable segments are Global Generics, Pharmaceutical Services and Active Ingredients, and Others. Global Generics is the largest contributor to revenue and covers prescription and over-the-counter finished products, with increased focus on complex products, injectables and specialty molecules in regulated markets such as the United States and Europe. That segment includes its biologics business and the nicotine replacement therapy business acquired from Haleon UK Enterprises Limited through Northstar Switzerland SARL in September 2024, which includes the Nicotinell and Nicabate brands. The company is expanding in biosimilars through development and commercialization partnerships, including a 2024 partnership with Alvotech for a denosumab biosimilar candidate in the United States and Europe and a 2025 partnership with Shanghai Henlius Biotech for the daratumumab biosimilar HLX15. It also has a partnership with Nestlé Health Science India for nutritional and wellness products in India. Its Others segment includes Aurigene Oncology, a discovery stage company developing therapies in oncology and inflammation. | Product or program | What it is | Stage | |---|---|---| | Global Generics portfolio | Prescription and over-the-counter finished products, including branded formulations and generics | | | Nicotinell and Nicabate | Consumer nicotine replacement brands from the Haleon acquisition, sold outside the United States | | | Denosumab biosimilar candidate | Biosimilar to Prolia and Xgeva, commercialized with Alvotech in the US and Europe | candidate | | HLX15 | Daratumumab biosimilar, commercialized with Shanghai Henlius Biotech in the US and Europe | | | Aurigene Oncology | Discovery stage biotechnology work in oncology and inflammation, through collaborations | discovery stage | Summarised from the company's [20-F filed May 29, 2026](https://www.sec.gov/Archives/edgar/data/1135951/000157587226000381/rdy0899_20f.htm). ## Dr. Reddy's Laboratories annual financials | Line | FY ended Mar 31, 2025 | FY ended Mar 31, 2024 | |---|---|---| | Revenue | [$3.81 billion](https://www.sec.gov/Archives/edgar/data/1135951/000157587225000393/) | [$3.35 billion](https://www.sec.gov/Archives/edgar/data/1135951/000157587224000660/) | | Research and development | [$320.0 million](https://www.sec.gov/Archives/edgar/data/1135951/000157587225000393/) | [$274.0 million](https://www.sec.gov/Archives/edgar/data/1135951/000157587224000660/) | | Net income (loss) | [$671.0 million](https://www.sec.gov/Archives/edgar/data/1135951/000157587225000393/) | [$668.0 million](https://www.sec.gov/Archives/edgar/data/1135951/000157587224000660/) | | Cash from operations | [$545.0 million](https://www.sec.gov/Archives/edgar/data/1135951/000157587225000393/) | [$545.0 million](https://www.sec.gov/Archives/edgar/data/1135951/000157587224000660/) | | Cash and equivalents | [$172.0 million](https://www.sec.gov/Archives/edgar/data/1135951/000157587225000393/) | [$85.0 million](https://www.sec.gov/Archives/edgar/data/1135951/000157587224000660/) | | Short-term investments | [$506.0 million](https://www.sec.gov/Archives/edgar/data/1135951/000157587225000393/) | [$892.0 million](https://www.sec.gov/Archives/edgar/data/1135951/000157587224000660/) | Latest balance sheet, Mar 31, 2025 (20-F): cash and equivalents $172.0 million, plus short-term investments of $506.0 million, $678.0 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Dr. Reddy's Laboratories What is the ticker symbol of Dr. Reddy's Laboratories? Dr. Reddy's Laboratories Ltd. trades under the ticker DRREDDY on NSE. Where is Dr. Reddy's Laboratories listed? Dr. Reddy's Laboratories Ltd. is listed on NSE. Our directory also records these other listings: BMFBOVESPA:R1DY34; BSE:DRREDDY; NYSE:RDY. What is the SEC CIK of Dr. Reddy's Laboratories? The SEC Central Index Key (CIK) for Dr. Reddy's Laboratories Ltd. is 1135951. Its filings are on SEC EDGAR. How many shares does Dr. Reddy's Laboratories have outstanding? 834,656,970 shares as of 2026-03-31, per the cover page of its 20-F filed 2026-05-29. Which country or territory is Dr. Reddy's Laboratories listed under? Our directory records Dr. Reddy's Laboratories Ltd. under India. What does Dr. Reddy's Laboratories do? Our directory classifies Dr. Reddy's Laboratories Ltd. as: Biopharma / pharmaceutical profile checked. This is a directory classification, not a description of the pipeline. What is the ISIN of Dr. Reddy's Laboratories? The ISIN recorded for Dr. Reddy's Laboratories Ltd. is INE089A01031. Does aibio.space cover Dr. Reddy's Laboratories? aibio.space lists Dr. Reddy's Laboratories Ltd. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Dr. Reddy's Laboratories incorporated? SEC records list its state or country of incorporation as K7. What does Dr. Reddy's Laboratories develop? Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company, established in 1984, that aims to accelerate access to affordable and innovative medicines. What is Global Generics portfolio from Dr. Reddy's Laboratories? Global Generics portfolio: Prescription and over-the-counter finished products, including branded formulations and generics What is Nicotinell and Nicabate from Dr. Reddy's Laboratories? Nicotinell and Nicabate: Consumer nicotine replacement brands from the Haleon acquisition, sold outside the United States What was Dr. Reddy's Laboratories's revenue last year? $3.81 billion for the fiscal year ended Mar 31, 2025, as reported to the SEC. Is Dr. Reddy's Laboratories profitable? Dr. Reddy's Laboratories Ltd. reported net income of $671.0 million for the fiscal year ended Mar 31, 2025, and generated $545.0 million of cash from operations, per its annual report to the SEC. How much does Dr. Reddy's Laboratories spend on research and development? $320.0 million in the fiscal year ended Mar 31, 2025, per its annual report. ## Investor discussion: Dr. Reddy's Laboratories Members talk about Dr. Reddy's Laboratories (DRREDDY). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Dr. Reddy's Laboratories, newest first. Each line links the filing it comes from. 1. 2026-04-08 Mergers Reported a merger or acquisition agreement. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1135951/000157587226000236/rdy0883_ex99-1.htm) 2. 2025-10-29 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1135951/000157587225000650/rdy0816_ex99-1.htm) 3. 2025-09-11 Mergers Reported a merger or acquisition agreement. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1135951/000157587225000570/rdy0801_ex99-1.htm) 4. 2025-01-08 Mergers Reported a merger or acquisition agreement. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1135951/000157587225000015/drr0710_ex99-1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NSE:DRREDDY on TradingView](https://www.tradingview.com/symbols/NSE-DRREDDY/). ## SEC filings and registration - **SEC name**: Dr Reddys Laboratories Ltd - **CIK**: 1135951 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: RDY (NYSE) - **State or country of incorporation**: K7 - **Fiscal year ends**: March 31 - **Filer category**: Large accelerated filer - **Business address**: 8-2-337, ROAD NO.3 BANJARA HILLS, HYDERABAD, 500-034 - **Phone**: 91 40 49002900 - **Shares outstanding**: 834,656,970 as of 2026-03-31 (20-F filed 2026-05-29) ### Recent filings (8-K and 6-K are the company's own announcements) - [6-K](https://www.sec.gov/Archives/edgar/data/1135951/000157587226000715/rdy0949_6k.htm) filed 2026-10-21 - [6-K](https://www.sec.gov/Archives/edgar/data/1135951/000157587226000700/rdy0948_6k.htm) filed 2026-10-14 - [6-K](https://www.sec.gov/Archives/edgar/data/1135951/000157587226000683/rdy0947_6k.htm) filed 2026-10-08 - [6-K](https://www.sec.gov/Archives/edgar/data/1135951/000157587226000677/rdy0946_6k.htm) filed 2026-10-07 - [6-K](https://www.sec.gov/Archives/edgar/data/1135951/000157587226000672/rdy-0945_6k.htm) filed 2026-10-05 - [6-K](https://www.sec.gov/Archives/edgar/data/1135951/000157587226000661/rdy0944_6k.htm) filed 2026-09-22 - [6-K](https://www.sec.gov/Archives/edgar/data/1135951/000157587226000659/rdy0943_6k.htm) filed 2026-09-21 - [6-K](https://www.sec.gov/Archives/edgar/data/1135951/000157587226000657/rdy0942_6k.htm) filed 2026-09-18 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001135951), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Dr. Reddy's Laboratories Ltd. is a public biotech or pharmaceutical company listed on NSE under the ticker DRREDDY, recorded under India. The directory classifies it as Biopharma / pharmaceutical profile checked. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Dr. Reddy's Laboratories Ltd. - **Ticker**: DRREDDY - **Listing**: NSE - **Country or territory**: India - **Business scope**: Biopharma / pharmaceutical profile checked - **ISIN**: INE089A01031 - **Other listed symbols**: BMFBOVESPA:R1DY34; BSE:DRREDDY; NYSE:RDY - **Last quote in directory**: 2026-10-22 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NSE-DRREDDY/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/dr-reddy-s-laboratories/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Dr. Reddy's Laboratories (DRREDDY) stock and investor profile", 2026-10-31, https://aibio.space/companies/dr-reddy-s-laboratories/